IBB - iShares Nasdaq Biotechnology ETF
| Assets | $10.15B |
| NAV | $153.29 |
| Expense Ratio | 0.46% |
| PE Ratio | 20.82 |
| Beta (5Y) | 0.97 |
| Dividend (ttm) | $0.39 |
| Dividend Yield | 0.25% |
| Ex-Dividend Date | Mar 25, 2021 |
| 1-Year Return | - |
| Trading Day | April 19 |
| Last Price | $151.58 |
| Previous Close | $153.26 |
| Change ($) | -1.68 |
| Change (%) | -1.10% |
| Day's Open | 152.52 |
| Day's Range | 150.68 - 153.67 |
| Day's Volume | 2,030,248 |
| 52-Week Range | 119.37 - 173.89 |
Fund Description
The investment seeks to track the investment results of the NASDAQ Biotechnology Index, which contains securities of companies listed on NASDAQ that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by Nasdaq, Inc. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
| Asset Class Equity | Sector Biotech |
| Region Global | Inception Date Feb 5, 2001 |
| Exchange NASDAQ | Ticker Symbol IBB |
| Index Tracked NASDAQ Biotechnology Index | |
Top 10 Holdings
45.23% of assets| Name | Symbol | Weight |
|---|---|---|
| Amgen | AMGN | 9.30% |
| Gilead Sciences | GILD | 7.01% |
| Illumina | ILMN | 4.97% |
| Vertex Pharmaceuticals | VRTX | 4.71% |
| Moderna | MRNA | 4.47% |
| Regeneron Pharmaceuticals | REGN | 4.32% |
| Biogen | BIIB | 3.47% |
| Alexion Pharmaceuticals | ALXN | 2.85% |
| Seagen | SGEN | 2.23% |
| AstraZeneca | AZN | 1.89% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 25, 2021 | $0.131059 | Mar 31, 2021 |
| Dec 14, 2020 | $0.0655 | Dec 18, 2020 |
| Sep 23, 2020 | $0.063 | Sep 29, 2020 |
| Jun 15, 2020 | $0.127 | Jun 19, 2020 |
| Mar 25, 2020 | $0.0554 | Mar 31, 2020 |
| Dec 16, 2019 | $0.0578 | Dec 20, 2019 |
At this point, investors are best off with a pick-and-choose strategy.
Biotechnology sector-related exchange traded funds could stumble in the near-term as increased regulatory scrutiny weighs on drugmakers. Among the hardest hit areas of Tuesday, the ALPS Medical Breakthr...
Biotech is ‘the superhero of the pandemic': investor
Antoine Papiernik, managing partner at Sofinnova Partners, joins Yahoo Finance to discuss trends in biotech and impacts the pandemic had on scientific discoveries.
Short-term investors may not see the long-term potential.
Stocks: Biotech and the outlook for vaccine stocks over the next 3-5 years
Yahoo Finance's Julie Hyman and Myles Udland spoke to Oppenheimer & Co. Analyst Hartaj Singh about the outlook for vaccine stocks.
Here we discuss a few ETFs that can enrich investors' portfolio in March amid a strong wave of optimism surrounding the coronavirus vaccine and introduction of another round of fiscal stimulus.
Biotech ETFs are climbing Wednesday as the Food and Drug Administration's staff endorsed Johnson & Johnson's coronavirus vaccine for emergency use, a key step in offering a third vaccination to the U.S....
Biotech stocks offer a textbook retracement pattern. The risk is low, and the reward is high.
Biotechnology sector-related exchange traded funds strengthened after Illumina (NasdaqGS: ILMN) announced better-than-expected quarterly earnings and an optimistic 2021 outlook. On Friday, the VanEck Ve...
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.
The Biden portfolio
The stocks most likely to get a boost from the new administration. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Karen Finerman, and Steve Grasso.
Due to lucrative risk/reward setups and heightened fundamental demand, many active traders will be watching biotech stocks.
Why this health-care strategist says the sector will rally into 2021
CNBC's Kelly Evans discusses the healthcare sector as well as biotech and pharma stocks and why the rally in these names can continue into 2021 with Jefferies' Jared Holz.
Both stock index ETFs and biotech stocks and ETFs have been on a tear lately thanks to promising coronavirus vaccine developments from several major pharmaceutical companies. But this week, the U.K. bec...
Those of you who are new to the Daily, you probably noticed the references to the Economic Modern Family. Mish developed one index and five sectors as the nucleus of the Family to help you and herself s...
November has been a big month for stock and biotech ETFs, and with the Federal Aviation Administration announcing that it supported the “first mass air shipment” of coronavirus vaccines on Friday, pharm...
Biotech stocks are likely to remain in focus through year end amid news surrounding COVID-19 vaccines and treatments.
Healthcare stocks and ETFs are continuing to outperform as investors are optimistic about an upcoming vaccine for the coronavirus, which has been a blight on the globe since early this year. There has b...
President Trump issues two 'groundbreaking' rules to lower drug prices
President Trump speaks on two new rules that will limit the price of drugs in the U.S. One rule will require discounts to be passed to patients. The second will require drugs for Medicare to be based on...
Biotech ETFs are getting a boost along with stocks on Monday thanks to Moderna, which announced that its initial phase three trial data reveals a coronavirus vaccine that is over 94% effective. Shares o...
Monday saw stocks and index ETFs surge, after the announcement from Pfizer that the pharmaceutical giant had a vaccine candidate with an over 90% effectiveness in clinical trials. Now another biotech, M...
Biotech companies need capital, but challenge is finding high quality management teams: Cowen CEO
On Monday, Pfizer announced a successful phase 3 trial, showing the vaccine to be more than 90 percent effective. This comes as the FDA gave emergency use authorization to Eli Lilly's antibody treatment.
Final Trades: MRVL, EEM, IBB & CHWY
The traders make their final trades of the week.
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their third-quarter earnings releases amid the coronavirus crisis.
The election year and the coronavirus has highlighted the importance of an adaptive health industry that meets up with quickly changing times. Investors can also tap into this evolution in healthcare th...
Institutional investors top biotech analyst on race for Covid treatment
Umer Raffat, Evercore ISI biotech analyst, on coronavirus treatments as cases start to rise around the country. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Karen Finerman...
In spite of no passing government stimulus, mixed economic data, rising covid cases and a wild pre election season, for the first time since we can remember, our core stock market ETFs are brushing off ...
Regardless of lockdowns or otherwise, these biotech stocks are positioned to rally strongly in the weeks and months ahead The post 3 Biotech Stocks to Buy Right Now appeared first on InvestorPlace. More...
Vertex Pharmaceuticals (VRTX) sold off on heavy volume after discontinuing trials of a promising liver disease treatment.
With less than a month until the election, and Democratic challenger Joe Biden opening up a wide lead, two market analysts lay out how to trade the politically sensitive health-care sector.
With Regeneron Pharmaceuticals and Eli Lilly & Company requesting the FDA for an Emergency Use Authorization for their antibody therapy treatments, the biotech space is filled with optimism.
Here we discuss ETFs that can be a good addition for enhanced portfolio returns in the fourth quarter of 2020.
The progress in Trump's health condition and his treatment protocols are continuously under the purview of market participants and are impacting Wall Street movements.
The race to introduce vaccine and treatment of coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.
Here are the ETFs to watch as biotech names bounce
Kevin O'Leary, O'Shares ETFs chairman, and Jim Lowell, Advisor Investments, join 'ETF Edge' on 'The Fast Money Halftime Report' discuss the bounce in biotech ETFs following news that President Trump is ...
Johnson & Johnson's entry into the late-stage trials has increased optimism in the coronavirus vaccine development.
Health care is again at a political crossroads heading into the U.S. presidential election. Gina Sanchez of Chantico Global and Craig Johnson of Piper Sandler discuss the potential winners and losers in...
With companies like Pfizer (PFE) giving possible hope for an end of year vaccine and a recent gap up in Nasdaq Biotechnology ETF (IBB), now could be a good time to keep an eye on newer issues in this se...
The novel coronavirus is weighing on the market, but these four biotech stocks can survive. Here's what you need to know to profit now.
The Final Trade: IBB, NFLX, PLNT & PTON
The traders offer their final stock picks of the week.
Coronavirus vaccine breakdown: The race for a COVID-19 vaccine
Meghan Fitzgerald Columbia University Health care Policy Professor discusses COVID-19 vaccine devlopment.